Mubritinib
From Wikipedia, the free encyclopedia
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H23F3N4O2 |
Molar mass | 468.480 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer.[1][2][3] It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.[4]
Synthesis[]
See also[]
- Protein kinase inhibitor
References[]
- ^ McCormick F, Fabbro D (2005). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. doi:10.1385/1-59259-962-1:001. ISBN 1-58829-384-X.
- ^ Mitscher LA, Lednicer D (1977). The organic chemistry of drug synthesis. New York: Wiley. ISBN 0-470-10750-2.
- ^ Lednicer D (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 978-0-470-19039-5.
- ^ Clinical trial number NCT00034281 for "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2" at ClinicalTrials.gov
Intracellular chemotherapeutic agents / antineoplastic agents (L01) | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SPs/MIs (M phase) |
| ||||||||||||||||||||||||||||
DNA replication inhibitor |
| ||||||||||||||||||||||||||||
Photosensitizers/PDT |
| ||||||||||||||||||||||||||||
Other |
| ||||||||||||||||||||||||||||
|
Targeted cancer therapy / antineoplastic agents (L01) | |||||||||
---|---|---|---|---|---|---|---|---|---|
CI monoclonal antibodies ("-mab") |
| ||||||||
Tyrosine kinase inhibitors ("-nib") |
| ||||||||
Other |
|
Growth factor receptor modulators | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Angiopoietin |
| ||||||||||
CNTF |
| ||||||||||
EGF (ErbB) |
| ||||||||||
FGF |
| ||||||||||
HGF (c-Met) |
| ||||||||||
IGF |
| ||||||||||
LNGF (p75NTR) |
| ||||||||||
PDGF | |||||||||||
RET (GFL) |
| ||||||||||
SCF (c-Kit) |
| ||||||||||
TGFβ |
| ||||||||||
Trk |
| ||||||||||
VEGF |
| ||||||||||
Others |
|
Retrieved from ""
Categories:
- Drugs not assigned an ATC code
- Tyrosine kinase inhibitors
- Oxazoles
- Triazoles
- Trifluoromethyl compounds
Hidden categories:
- Drugs with non-standard legal status
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles containing unverified chemical infoboxes